HAEMONETICS CORP 4
4 · HAEMONETICS CORP · Filed Oct 25, 2013
Insider Transaction Report
Form 4
Jesse Sandra
VP & CLO
Transactions
- Award
Common Stock
2013-10-23+3,060→ 11,740 total - Award
Non-Qualified Stock Option (right to buy)
2013-10-23+28,523→ 28,523 totalExercise: $41.66From: 2019-10-23Exp: 2023-10-23→ Common Stock (28,523 underlying)
Holdings
- 30,740
Non-Qualified Stock Option (right to buy)
Exercise: $30.67From: 2012-10-25Exp: 2018-10-25→ Common Stock (30,740 underlying) - 28,614
Non-Qualified Stock Option (right to buy)
Exercise: $39.05From: 2013-10-24Exp: 2019-10-24→ Common Stock (28,614 underlying) - 25,000
Performance Shares
Exercise: $0.00From: 2017-03-31Exp: 2017-12-31→ Common Stock (25,000 underlying)
Footnotes (3)
- [F1]Restricted Stock Unit Grant which vest 25% per year over 4 years following the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan.
- [F2]Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.
- [F3]Market Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Market Stock Unit based on Haemonetics stock price during the 30 trading days prior to March 31, 2017. The number of Market Stock Units (and therefore the number of shares payable) will depend on the Companys stock price during such period. The Market Stock Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to three times the target amount in column 5. The Market Stock Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d).